HOME >> MEDICINE >> NEWS
Injectable drug, combined with counseling, shows promise in treating alcohol dependence

overing how best to provide treatment -- like adding a safe medication to counseling. A long-acting injectable, which eliminates the burden of daily pill taking, will open new doors for our patients and give hope to them and their families," adds Dr. Pettinati.

A total of 627 alcohol-dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. In addition to an injection, all participants received low-intensity counseling consisting of 12 sessions during the six-month study, in addition to study medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six-month treatment period. In addition, long-acting naltrexone was generally well tolerated and side effects were predominantly mild and decreased over time. (The three most common side effects reported were nausea, headache and fatigue.)

The study was one of the largest trials of a medication for alcohol dependence and was conducted at 24 sites nationwide, including public, private hospitals and Veterans Administration clinics and tertiary-care medical centers. Other study authors included researchers from the medical schools at the University of Connecticut, Yale University, and Harvard University, and from Alkermes Incorporated, a biotechnology company based in Cambridge, Mass., that manufactures the long-acting naltrexone formulation (Vivitrex) used in the study.


'"/>

Contact: Ed Federico
ed.federico@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
5-Apr-2005


Page: 1 2

Related medicine news :

1. Mistletoe is not an anti-cancer drug, say doctors
2. RAND study shows solitary drug, alcohol and cigarette use puts adolescents at higher risk
3. The Journal of Clinical Pharmacology looks at effects of smoking cessation drug, varenicline
4. Stubborn ulcerative colitis responds to arthritis drug, review finds
5. Brain power combined to form new $125M institute
6. New study demonstrates combined techniques to detect, monitor Alzheimers disease
7. TPV EU approval provides new HIV active drug to be combined with FUZEON
8. 1.7m to build worlds first SIMS instrument combined with infra-red spectroscopy
9. Antibody combined with cancer drug shows promise against breast tumors
10. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
11. Medication combined with behavior therapy works best for ADHD children, study finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to meet talent shortages ... outdated healthcare executive resume. , “If you’re a healthcare executive open to new opportunities ... if it’s as ready as you are for a new job search. I’ve heard ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 2017 Halo Labs announces the launch of ... system called the Horizon at PEGS 2017 in ... system analyzes sub visible particulate matter in biopharmaceutical samples ... as early as candidate selection and pre-formulation. ... research organization Elion Labs for system validation. ...
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
Cached News: